<--- Back to Details
First PageDocument Content
Organic chemistry / Guanidines / GlaxoSmithKline / Oseltamivir / Zanamivir / Antiviral drug / Influenza / Influenza treatment / Flu pandemic / Neuraminidase inhibitors / Chemistry / Acetamides
Date: 2012-10-22 14:28:54
Organic chemistry
Guanidines
GlaxoSmithKline
Oseltamivir
Zanamivir
Antiviral drug
Influenza
Influenza treatment
Flu pandemic
Neuraminidase inhibitors
Chemistry
Acetamides

Microsoft Word - Antivirals survey rev.doc

Add to Reading List

Source URL: www.cpsp.cps.ca

Download Document from Source Website

File Size: 73,00 KB

Share Document on Facebook

Similar Documents

Visterra’s Monoclonal Antibody in Development for the Treatment of Influenza A, VIS410, Demonstrated Significant Antiviral Activity and Reduced Duration of Respiratory Symptoms in Phase 2a Challenge Study – Study Ach

DocID: 1vb6O - View Document

FDA Grants Fast Track Designation to Visterra’s VIS410 for Treatment of Hospitalized Patients with Influenza A - Company Plans to Initiate Phase 2b Clinical Trial in Early 2018 Cambridge, MA – November 1, 2017 – Vi

DocID: 1uP0v - View Document

Visterra’s Monoclonal Antibody in Development for the Treatment of Influenza A, VIS410, Demonstrated Significant Antiviral Activity and Reduced Duration of Respiratory Symptoms in Phase 2a Challenge Study – Study Ach

DocID: 1uOXA - View Document

XOFLUZATM (Baloxavir Marboxil) Tablets 10mg/20mg Approved for the Treatment of Influenza Types A and B in Japan Osaka, Japan, February 23, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi,

DocID: 1uL4E - View Document

January 14, 2015 LACDPH Health Update: ACCESS TO ANTIVIRAL MEDICATION FOR TREATMENT OF INFLUENZA This message is intended for pharmacies and healthcare facilities as well as emergency medicine, internal medicine, urgent

DocID: 1rZMZ - View Document